182 related articles for article (PubMed ID: 31399494)
1. Simultaneous Assessment of Hepatic Transport and Metabolism Pathways with a Single Probe Using Individualized PBPK Modeling of
Franchetti Y; Nolin TD
J Pharmacol Exp Ther; 2019 Oct; 371(1):151-161. PubMed ID: 31399494
[TBL] [Abstract][Full Text] [Related]
2. Application of Individualized PBPK Modeling of Rate Data to Evaluate the Effect of Hemodialysis on Nonrenal Clearance Pathways.
Franchetti Y; Nolin TD
J Clin Pharmacol; 2021 Jun; 61(6):769-781. PubMed ID: 33459400
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin.
Paine MF; Wagner DA; Hoffmaster KA; Watkins PB
Clin Pharmacol Ther; 2002 Nov; 72(5):524-35. PubMed ID: 12426516
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C(14)-erythromycin breath test and the antipyrine clearance test.
Michael M; Cullinane C; Hatzimihalis A; O'Kane C; Milner A; Booth R; Schlicht S; Clarke SJ; Francis P
Cancer Chemother Pharmacol; 2012 Jan; 69(1):125-35. PubMed ID: 21626050
[TBL] [Abstract][Full Text] [Related]
5. Erythromycin breath test and clinical transplantation.
Watkins PB
Ther Drug Monit; 1996 Aug; 18(4):368-71. PubMed ID: 8857552
[TBL] [Abstract][Full Text] [Related]
6. The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity.
Kurnik D; Wood AJ; Wilkinson GR
Clin Pharmacol Ther; 2006 Sep; 80(3):228-34. PubMed ID: 16952489
[TBL] [Abstract][Full Text] [Related]
7. Is quinine a suitable probe to assess the hepatic drug-metabolizing enzyme CYP3A4?
Wanwimolruk S; Paine MF; Pusek SN; Watkins PB
Br J Clin Pharmacol; 2002 Dec; 54(6):643-51. PubMed ID: 12492613
[TBL] [Abstract][Full Text] [Related]
8. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance.
Hirth J; Watkins PB; Strawderman M; Schott A; Bruno R; Baker LH
Clin Cancer Res; 2000 Apr; 6(4):1255-8. PubMed ID: 10778948
[TBL] [Abstract][Full Text] [Related]
9. Quantitative Analyses of the Influence of Parameters Governing Rate-Determining Process of Hepatic Elimination of Drugs on the Magnitudes of Drug-Drug Interactions via Hepatic OATPs and CYP3A Using Physiologically Based Pharmacokinetic Models.
Yoshikado T; Maeda K; Kusuhara H; Furihata KI; Sugiyama Y
J Pharm Sci; 2017 Sep; 106(9):2739-2750. PubMed ID: 28495568
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of cytochrome P4503A substrates in vivo administered by the same route: lack of correlation between alfentanil clearance and erythromycin breath test.
Krivoruk Y; Kinirons MT; Wood AJ; Wood M
Clin Pharmacol Ther; 1994 Dec; 56(6 Pt 1):608-14. PubMed ID: 7995002
[TBL] [Abstract][Full Text] [Related]
11. Influence of solute carriers on the pharmacokinetics of CYP3A4 probes.
Franke RM; Baker SD; Mathijssen RH; Schuetz EG; Sparreboom A
Clin Pharmacol Ther; 2008 Dec; 84(6):704-9. PubMed ID: 18509328
[TBL] [Abstract][Full Text] [Related]
12. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice.
Veronese ML; Gillen LP; Burke JP; Dorval EP; Hauck WW; Pequignot E; Waldman SA; Greenberg HE
J Clin Pharmacol; 2003 Aug; 43(8):831-9. PubMed ID: 12953340
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
Budha NR; Ji T; Musib L; Eppler S; Dresser M; Chen Y; Jin JY
Clin Pharmacokinet; 2016 Nov; 55(11):1435-1445. PubMed ID: 27225997
[TBL] [Abstract][Full Text] [Related]
14. Integration of Food Animal Residue Avoidance Databank (FARAD) empirical methods for drug withdrawal interval determination with a mechanistic population-based interactive physiologically based pharmacokinetic (iPBPK) modeling platform: example for flunixin meglumine administration.
Li M; Cheng YH; Chittenden JT; Baynes RE; Tell LA; Davis JL; Vickroy TW; Riviere JE; Lin Z
Arch Toxicol; 2019 Jul; 93(7):1865-1880. PubMed ID: 31025081
[TBL] [Abstract][Full Text] [Related]
15. The erythromycin breath test for the prediction of drug clearance.
Rivory LP; Slaviero KA; Hoskins JM; Clarke SJ
Clin Pharmacokinet; 2001; 40(3):151-8. PubMed ID: 11327195
[TBL] [Abstract][Full Text] [Related]
16. Optimizing the erythromycin breath test for use in cancer patients.
Rivory LP; Slaviero K; Seale JP; Hoskins JM; Boyer M; Beale PJ; Millward MJ; Bishop JF; Clarke SJ
Clin Cancer Res; 2000 Sep; 6(9):3480-5. PubMed ID: 10999732
[TBL] [Abstract][Full Text] [Related]
17. Comparison of urinary 6-beta-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity.
Watkins PB; Turgeon DK; Saenger P; Lown KS; Kolars JC; Hamilton T; Fishman K; Guzelian PS; Voorhees JJ
Clin Pharmacol Ther; 1992 Sep; 52(3):265-73. PubMed ID: 1526083
[TBL] [Abstract][Full Text] [Related]
18. Effects of metronidazole on hepatic CYP3A4 activity.
Haas CE; Kaufman DC; DiCenzo RC
Pharmacotherapy; 2001 Oct; 21(10):1192-5. PubMed ID: 11601665
[TBL] [Abstract][Full Text] [Related]
19. Measurement of hepatic and intestinal CYP3A4 and PGP activity by combined po + iv [14C]erythromycin breath and urine test.
Lemahieu WP; Maes BD; Ghoos Y; Rutgeerts P; Verbeke K; Vanrenterghem Y
Am J Physiol Gastrointest Liver Physiol; 2003 Sep; 285(3):G470-82. PubMed ID: 12909563
[TBL] [Abstract][Full Text] [Related]
20. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans.
Mouly S; Lown KS; Kornhauser D; Joseph JL; Fiske WD; Benedek IH; Watkins PB
Clin Pharmacol Ther; 2002 Jul; 72(1):1-9. PubMed ID: 12151999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]